ATLANTA, Sept. 26, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 31st Annual Leveraged Finance Conference on Tuesday, October 3, 2023. The Company's presentation is scheduled to begin at 10:40 a.m. MST.
A live webcast of the presentation will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.
Contacts: | ||
Artivion | Gilmartin Group LLC | |
D. Ashley Lee | Brian Johnston / Lynn Lewis | |
Executive Vice President & | Phone: 332-895-3222 | |
Chief Financial Officer | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
Phone: 770-419-3355 | ||
Last Trade: | US$30.99 |
Daily Change: | 0.40 1.31 |
Daily Volume: | 290,493 |
Market Cap: | US$1.300B |
January 27, 2025 November 07, 2024 October 10, 2024 August 08, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load